Relative contribution of angiotensin II, bradykinin, and prostaglandins to the renal effects of converting enzyme inhibition in rats after chronic myocardial infarction

Journal of Cardiovascular Pharmacology

Volumn 28, Issue 1, 1996, Pages 167-174

  Deck, Carlos C ^a   Gaballa, Mohamed A ^a   Raya, Thomas E ^a,b  

^a UNIVERSITY OF ARIZONA   (United States)

^b SOUTHERN ARIZONA VA HEALTH CARE SYSTEM   (United States)

Author keywords

Angiotensin II; Bradykinin; Heart failure; Myocardial infarction; Prostaglandin

Indexed keywords

ANGIOTENSIN; BRADYKININ; CAPTOPRIL; LOSARTAN; PROSTAGLANDIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DRUG EFFECT; ENZYME INHIBITION; GLOMERULUS FILTRATION RATE; HEART INFARCTION; KIDNEY BLOOD FLOW; KIDNEY VASCULAR RESISTANCE; MALE; MEAN ARTERIAL PRESSURE; MICTURITION; NATRIURESIS; NONHUMAN; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BIPHENYL COMPOUNDS; BRADYKININ; CAPTOPRIL; CYCLOOXYGENASE INHIBITORS; HEMODYNAMIC PROCESSES; IMIDAZOLES; INDOMETHACIN; KIDNEY; KIDNEY FUNCTION TESTS; LOSARTAN; MALE; MYOCARDIAL INFARCTION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, BRADYKININ; TETRAZOLES;

EID: 0029951643     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199607000-00024     Document Type: Article

References (35)

1. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration cooperative study. N Engl J Med 1986;314:1547-52.
2. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-35.
3. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
4. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303-10.
5. Pfeffer MA, Braunwald E, Moyé LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992;327:669-77.
6. Thurston H, Swales JD. Converting enzyme inhibitor and saralasin infusion in rats: evidence for an additional vasodepressor property of converting enzyme inhibitor. Circ Res 1978;42:588-92.
7. Dzau VJ, Swartz SL. Dissociation of the prostaglandin and renin angiotensin systems during captopril therapy for chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1987;60:1101-5.
8. Gavras I. Bradykinin-mediated effects of ACE inhibition. Kidney Int 1992;42:1020-9.
9. Ichikawa I, Pfeffer JM, Pfeffer MA, Hostetter TH, Brenner BM. Role of angiotensin II in the altered renal function of congestive heart failure. Circ Res 1984;55:669-75.
10. DiBona GF, Herman PJ, Sawin LL. Neural control of renal function in edema-forming states. Am J Physiol 1988;254:R1017-24.
11. Hostetter TH, Pfeffer JM, Pfeffer MA, Dworkin LD, Braunwald E, Brenner BM. Cardiorenal hemodynamics and sodium excretion in rats with myocardial infarction. Am J Physiol 1983;245:H98-103.
12. Kon V, Yared A, Ichikawal I. Role of renal sympathetic nerves in mediating hypoperfusion of renal cortical micro-circulation in experimental congestive heart failure and acute extracellular fluid volume depletion. J Clin Invest 1985;76:1913-20.
13. Raine AEG. Renal abnormalities in congestive heart failure. In: Fozzard HA, ed. The heart and cardiovascular system, 2nd ed. New York: Raven Press, 1992:1379-91.
14. Schunkert H, Ingelfinger JR, Hirsch AT, et al. Evidence for tissue-specific activation of renal angiotensinogen mRNA expression in chronic stable experimental heart failure. J Clin Invest 1992;90:1523-9.
15. Schunkert H, Tang SS, Litwin SE, et al. Regulation of intrarenal and circulating renin-angiotensin systems in severe heart failure in the rat. Cardiovasc Res 1993;27:731-5.
16. Hall D, Zeitler H, Rudolph W. Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure. J Am Coll Cardiol 1992;20:1549-55.
17. Raya T, Gay RG, Lancaster L, Aguirre M, Moffett C, Goldman S. Serial changes in left ventricular relaxation and chamber stiffness after large myocardial infarction in rats. Circulation 1988;77:1424-31.
18. Raya TE, Lee RW, Westhoff T, Goldman S. Captopril restores hemodynamic responsiveness to atrial natriuretic peptide in rats with heart failure. Circulation 1989;80:1893-902.
19. Raya T, Gay R, Aguirre M, Goldman S. Importance of venodilatation in prevention of left ventricular dilatation after chronic large myocardial infarction in rats: a comparison of captopril and hydralazine. Circ Res 1989;64:330-7.
20. Raya TE, Fonken SJ, Lee RW, et al. Hemodynamic effects of direct angiotensin II blockade compared to converting enzyme inhibition in rat model of heart failure. Am J Hypertens 1991;4:3348-408.
21. Lee RW, Raya TE, Michael U, Foster S, Meeks T, Goldman S. Captopril and ANP: changes in renal hemodynamics, glomerular-ANP receptors, and guanylate cyclase activity in rats with heart failure. J Pharmacol Exp Ther 1991;260:347-54.
22. Gay R, Graham S, Aguirre M, Goldman S, Morkin E. Effects of 10 to 12 day treatment with L-thyroxine in rats with myocardial infarction. Am J Physiol 1988;255:H801-6.
23. Dixon WJ, Brown MB, Engelman L, Jennrich RI. BMDP statistical software manual, Berkeley: University of California Press, 1990.
24. Granger JP, Hall JE. Acute and chronic actions of bradykinin on renal function and arterial pressure. Am J Physiol 1985;248:F87-92.
25. 2 bradykinin receptors. FASEB J 1989;3:2019-25.
26. Schrör K. Role of prostaglandins in the cardiovascular effects of bradykinin and angiotensin-converting enzyme inhibitors. J Cardiovasc Pharmacol 1992;20:S68-73.
27. DeFelice A, Frering R, Horan P. Time course of hemody- namic changes in rats with healed myocardial infarction. Am J Physiol 1989;257:H289-96.
28. Pfeffer MA, Pfeffer JM, Steinberg C, Finn P. Survival after an experimental myocardial infarction: beneficial effects of long-term therapy with captopril. Circulation 1985;72:406-12.
29. Oster JR. Materson BJ. Renal and electrolyte complications of congestive heart failure and effects of therapy with angiotensin-converting enzyme inhibitors. Arch Intern Med 1992;152:704-10.
30. Fitzpatrick MA, Rademaker MT, Charles CJ, Yandle TG, Espiner EA, Ikram H. Angiotensin II receptor antagonism in ovine heart failure: acute hemodynamic, hormonal, and renal effects. Am J Physiol 1992;263:H250-6.
31. Dietz R, Nagel F, Osterziel KJ. Angiotensin-converting enzyme inhibitors and renal function after MI. Am J Cardiol 1992;70:119C-25C.
32. Brands MW, Alonso-Galicia M, Mizelle HL, Montani JP, Hildebrandt DA, Hall JE. Chronic angiotensin-converting-enzyme inhibition improves cardiac output and fluid balance during heart failure. Am J Physiol 1993;264:R414-22.
33. Mento PF, Maita ME, Murphy WR, Holt WF, Wilkes BM. Comparison of angiotensin converting enzyme and renin inhibition in rats following myocardial infarction. J Cardiovasc Pharmacol 1993;21:791-6.
34. Mattson DL, Roman RJ. Role of kinins and angiotensin II in the renal hemodynamic response to captopril. Am J Physiol 1991;260:F670-9.
35. Fenoy FJ, Scicli G, Carretero O, Roman RJ. Effect of an angiotensin II and a kinin receptor antagonist on the renal hemodynamic response to captoprii. Hypertension 1991;17:1038-44.